Positive Report for Lemaitre Vascular from Benchmark Co.

Lemaitre Vascular (NASDAQ: LMAT) received a Buy rating and a $40 price target from Benchmark Co. analyst Raymond Myers today. The company’s shares opened today at $35.88. According to TipRanks.com, Myers is More »

Needham Maintains Their Buy Rating on Global Blood Therapeutics

Needham analyst Danielle Brill maintained a Buy rating on Global Blood Therapeutics (NASDAQ: GBT) today and set a price target of $70. The company’s shares opened today at $45. Brill commented: “Here More »